Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Summary
| Human PD-L1 (Phe19-Thr239) Accession # Q9NZQ7 |
DIEGRMD | Human IgG1 (Pro100-Lys330) |
| N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
156-B7
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS and NaCl. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Data Image
View Larger
Recombinant Human PD-L1/B7-H1 Fc Chimera (Catalog # 156-B7) inhibits anti-CD3antibody-induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 2-10 μg/mL.
Reconstitution Calculator
Background: PD-L1/B7-H1
B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (2). Within the ECD, human B7-H1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). B7-H1 is expressed on
inflammatory-activated immune cells including macrophages, T cells, and B cells (4-7), keratinocytes (8, 9), enothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (11, 12). B7-H1 binds to T cell B7-1/CD80 and PD-1 (7, 8, 12-15). It suppresses T cell activation and proliferation (5, 8, 14, 16) and induces the apoptosis of activated T cells (11). It plays a role in the development of immune tolerance by promoting T cell anergy (7, 14) and enhancing regulatory T cell development (16). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (5, 10) and inhibits the development of Th17 cells (16). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (6, 9, 12, 15).
- Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
- Dong, H. et al. (1999) Nat. Med. 5:1365.
- Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
- Tamura, H. et al. (2001) Blood 97:1809.
- Chen, L. et al. (2007) J. Immunol. 178:6634.
- Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
- Tsushima, F. et al. (2007) Blood 110:180.
- Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
- Cao, Y. et al. (2010) Cancer Res. 71:1235.
- Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
- Dong, H. et al. (2002) Nat. Med. 8:793.
- Azuma, T. et al. (2008) Blood 111:3635.
- Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
- Park, J.-J. et al. (2010) Blood 116:1291.
- Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
- Herold, M. et al. (2015) J. Immunol. 195:3584.
Citations for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
10
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
Authors: A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki, T Takimoto, H Hirata, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka, M Kanazu, M Kuroyama, M Hamaguchi, T Koba, Y Futami, M Ishijima, Y Suga, Y Akazawa, H Machiyama, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda, H Kida, EA Akbay, PS Hammerman, KK Wong, G Dranoff, M Mori, T Kijima, A Kumanogoh
JCI Insight, 2018;3(19):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice
Authors: E Burova, A Hermann, J Waite, T Potocky, V Lai, S Hong, M Liu, O Allbritton, A Woodruff, Q Wu, A D'Orvillie, E Garnova, A Rafique, W Poueymirou, J Martin, T Huang, D Skokos, J Kantrowitz, J Popke, M Mohrs, D MacDonald, E Ioffe, W Olson, I Lowy, A Murphy, G Thurston
Mol. Cancer Ther, 2017;0(0):.
Species: N/A
Sample Types: Protein
Applications: Bioassay -
Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy
Authors: UM Vogl, L Öhler, M Rasic, JM Frischer, M Modak, J Stöckl
Anticancer Res., 2017;37(4):1947-1955.
Applications: ELISA (Standard) -
B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells
Sci Rep, 2016;6(0):36722.
Species: Human
Sample Types: Protein
Applications: ELISA (Standard) -
Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
Authors: Robert L Ferris
Oncoimmunology, 2016;5(10):e1200778.
Applications: Bioassay -
PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
Authors: Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane L, Ferris R
Cancer Res, 2015;75(3):508-18.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.
Authors: Melendreras S, Martinez-Camblor P, Menendez A, Bravo-Mendoza C, Gonzalez-Vidal A, Coto E, Diaz-Corte C, Ruiz-Ortega M, Lopez-Larrea C, Suarez-Alvarez B
PLoS ONE, 2014;9(12):e113396.
Species: Human
Sample Types: Serum
Applications: ELISA (Standard) -
IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells.
Authors: Chinnadurai R, Copland I, Patel S, Galipeau J
J Immunol, 2014;192(4):1491-501.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Authors: Steidl C, Shah SP, Woolcock BW
Nature, 2011;471(7338):377-81.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.
Authors: Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ
J. Immunol., 2006;177(12):8844-50.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsPrimary Antibodies
Recombinant Proteins
Reconstitution Buffers
Reviews for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
Average Rating: 4.9 (Based on 19 Reviews)
Have you used Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Reason for Rating: Binding observed.
SPR experiment
Using Octet, we tested the ability of B7-H1/PD-L1 to bind recombinant PD-1 (R&D 8986-PD-100) and found them to specifically bind to each other.
